Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, May 28 2021

Full Issue

Dems Assail GOP On Drug Pricing Bill, Yet Fail To Gain Support In Own Caucus

In a series of ads, Democrats complain that Republican lawmakers are refuse to support legislation to cap prescription drug prices. But the bills are also controversial among Democrats. The majority party is also having trouble coming up with ways to end long-standing GOP measures that limit federal funding on abortions and gun research.

Axios: House Democrats Attack GOP Over Drug Pricing Bill Many In Their Own Caucus Oppose 

House Democrats are following the money in a series of new ads hitting Republican opponents of major drug price legislation — but the trail also leads back to their own members. The Democratic Congressional Campaign Committee is accusing House Republicans of doing the bidding of drug industry donors by opposing the bill. Unremarked upon are the House Democrats who've also received money from the industry — and whose opposition is seen as potentially fatal to the legislation. (Markay, 5/27)

Roll Call: Senate Advances Science And Tech Bill

The Senate’s scientific research and development package got past a key hurdle on Thursday as the chamber voted 68-30 to invoke cloture on a substitute amendment by Majority Leader Charles E. Schumer, setting the legislation up for possible final passage later in the day. The sprawling substitute amendment, amended over the course of two weeks on the Senate floor to include proposals by both Republicans and Democrats, would authorize more than $100 billion in the next five fiscal years for a whole-of-government effort to compete with China’s quest for dominance in emerging fields of science and technology. (DeChiaro, 5/27)

In other news from Capitol Hill —

Politico: Democrats Are Stuck On Abortion And Gun Control. They Have A Backup Plan

Congressional Democrats dream of ditching long-held Republican bans that block abortion funding and stifle gun violence research. Even with total control in Washington, they still can’t make it happen. To soften that defeat, they're plotting to spend billions of dollars on reproductive health and gun violence prevention this year. (Emma, 5/27)

The Hill: Top Senate Republican Says 'Structural Reforms' Needed At CDC For Next Health Threat

Sen. Richard Burr (R-N.C.) issued a scathing memo criticizing the Centers for Disease Control and Prevention’s (CDC) response to the coronavirus pandemic, calling for “structural” reform of the agency following what he called “mistakes” responding to COVID-19. “Structural and cultural reforms at CDC are needed to ensure the organization is modern, nimble, mission-focused, and able to leverage cutting-edge science so that the United States is better prepared for the next threat that will come our way,” Burr, the top Republican on the Senate Health, Education, Labor and Pensions Committee, wrote in a five-page brief. (Axelrod, 5/27)

KHN: KHN’s ‘What The Health?’: The Return Of The Public Option

The “public option” is back — both in Washington, D.C., and the states. President Joe Biden as a candidate supported the idea of a government-run or heavily regulated insurance plan that would compete with private insurance. But until now it has been more of a concept than a plan. Two top health leaders in Congress say they will try to put a plan together, while public options in various forms work their way through legislatures in Colorado and Nevada. Meanwhile, bioethicists are debating whether the U.S. should be vaccinating low-risk adolescents against covid-19 while high-risk adults in other countries remain vulnerable. (5/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF